Novel experimental agent is highly active in CLL patients, interim study shows
An interim analysis of a phase Ib/II clinical trial indicates that a novel experimental agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other ...
Dec 11, 2011
0
0